These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 15077311)

  • 1. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
    Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
    Khurshudian AV
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study.
    Zandbelt MM; de Wilde P; van Damme P; Hoyng CB; van de Putte L; van den Hoogen F
    J Rheumatol; 2004 Jan; 31(1):96-101. PubMed ID: 14705226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.
    Pillemer SR; Brennan MT; Sankar V; Leakan RA; Smith JA; Grisius M; Ligier S; Radfar L; Kok MR; Kingman A; Fox PC
    Arthritis Rheum; 2004 Aug; 51(4):601-4. PubMed ID: 15334433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
    Ruperto N; Lovell DJ; Cuttica R; Wilkinson N; Woo P; Espada G; Wouters C; Silverman ED; Balogh Z; Henrickson M; Apaz MT; Baildam E; Fasth A; Gerloni V; Lahdenne P; Prieur AM; Ravelli A; Saurenmann RK; Gamir ML; Wulffraat N; Marodi L; Petty RE; Joos R; Zulian F; McCurdy D; Myones BL; Nagy K; Reuman P; Szer I; Travers S; Beutler A; Keenan G; Clark J; Visvanathan S; Fasanmade A; Raychaudhuri A; Mendelsohn A; Martini A; Giannini EH; ;
    Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome.
    Price EJ; Rigby SP; Clancy U; Venables PJ
    J Rheumatol; 1998 May; 25(5):896-9. PubMed ID: 9598887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
    Van Den Bosch F; Kruithof E; Baeten D; Herssens A; de Keyser F; Mielants H; Veys EM
    Arthritis Rheum; 2002 Mar; 46(3):755-65. PubMed ID: 11920412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
    Fox RI; Dixon R; Guarrasi V; Krubel S
    Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial.
    Korhonen T; Karppinen J; Paimela L; Malmivaara A; Lindgren KA; Bowman C; Hammond A; Kirkham B; Järvinen S; Niinimäki J; Veeger N; Haapea M; Torkki M; Tervonen O; Seitsalo S; Hurri H
    Spine (Phila Pa 1976); 2006 Nov; 31(24):2759-66. PubMed ID: 17108825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
    Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
    Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
    Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
    J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.